SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending due to its recent merger approval with HCYC, sparking significant after-hours volatility and a T12 regulatory halt pending further information requested by NASDAQ. Community chatter revolves around the potential for a massive squeeze reminiscent of other low-float runners, with some expressing concerns about a possible pump and dump scheme. The stock's association with Chinese companies and SPAC structures is also fueling speculation and caution.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community anticipates the release of 48-week data and feedback from an FDA meeting, with discussions focusing on the potential for AI to improve clinical trial outcomes. Positive community sentiment is fueled by the belief that recent news may de-risk the path to regulatory approval for their MASH treatment and position the company as a potential acquisition target. Some investors are closely watching short positions, expecting a possible squeeze if positive catalysts emerge.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to speculation around a potential merger, drawing comparisons to similar stocks that have experienced significant gains recently. The stock's low float and high borrow fees are fueling discussions of a potential short squeeze, with the community actively debating price targets and entry/exit strategies. Some traders are noting its similarity to $ATMC and anticipating a comparable surge.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 data for its multiple myeloma treatment, Burixafor, with community members citing the data as too good and the float as too low. Discussions revolve around a potential short squeeze, with some traders eyeing a move towards higher price levels. However, concerns about potential dilutions and cash runway are also circulating among investors.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining traction as community members express excitement with "caw caw" and highlight its multichain functionality. Many believe $CAW has strong potential, drawing comparisons to $DOGE and $SHIB, while others are focusing on its organic and deflationary nature. The community is actively awaiting potential listings on major exchanges.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending due to JPMorgan initiating coverage with an "Overweight" rating and a $43 price target, citing confidence in its lead drug candidate, telitacicept, and its blockbuster potential. The community is discussing the validity of the JPM price target, potential for a short squeeze, and milestone payments owed by the company. Some traders are eyeing specific price levels for entries and exits, while others express skepticism about the stock's long-term prospects.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

AFJK is trending due to its aggressive volatility and low float, leading to significant price swings and multiple trading halts; the community is closely watching for the stock to unhalt and potentially reach new highs. Speculation is fueled by its status as a SPAC seeking a merger target and comparisons to other low-float runners like $ATMC and $MTC, with some mentioning a potential United Hydrogen merger.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending due to an improved earnings and cash flow outlook through 2030, driven by gains with no increase in capital spending. The community is discussing the potential for increased oil and gas production and the company's disciplined capital allocation. Upstream oil stability and global energy tightness are also factors influencing the positive sentiment around XOM.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending amidst volatile trading, sparked by the appointment of Martin Shkreli as a strategic advisor, which has divided investors. While some see Shkreli's involvement as a positive catalyst given his contacts, others worry about his reputation and potential impact on the company's valuation, especially given the company's current lack of revenue and the sector's forward-looking nature.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is trending as the community discusses the launch of Midnight ($NIGHT) and its implications for privacy, while some express frustration with ADA's recent price performance and question its broader utility. BRICS, staking, and possible Fed moves are also circulating as potential catalysts; community members are closely monitoring if it can break resistance and sustain upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beneficient

BENF: F1Q26 Earnings - EPS Miss on Higher Expenses and Lower Shares Outstanding

Why Beneficient Stock Is Up Today

Beneficient shares are trading higher Friday after the company announced it has consummated a transaction to increase its permanent equity by $126 million. Here's a look at what's going on:
read more...

What's Going On With Beneficient Stock?

Beneficient shares are trading lower Monday. The company is set to release its postponed fourth-quarter and full-year financial results before the opening bell on Tuesday.
read more...

Beneficient Enters into New Liquidity Transaction with ff Venture Capital

- Related liquidity transactions with three funds managed by ff Venture Capital, a leading investor in emerging industries, including fintech - With full participation from all limited partners...

Beneficient Reports Results for Third Quarter Fiscal 2024

Further Developed GP Solutions Program, Launched New Products/Service and Improved Operational Efficiencies and Financial Position
 Portfolio Diversification

 Portfolio...

Beneficient Engages Leading Investor Relations Firm Darrow Associates to Enhance Capital Markets Presence

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Beneficient (Nasdaq: BENF) (the Company ), a technology-enabled platform providing liquidity and related trust and custody services to holders of...

Beneficient Announces Third Quarter Fiscal 2024 Earnings Release and Webcast

DALLAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) ( Ben or the Company ), a technology-enabled financial services holding company that provides liquidity and related trust and...

Beneficient Closes Initial Series of Liquidity Transaction Financings of Limited Partner Interests Sourced Through Preferred Liquidity Provider Program ( PLP Program )

Closing of $2 Million Liquidity Financing Caps Nearly $10 Million Sourced from PLP Program Entered into additional PLP Program Agreements, Increasing the Total Amount of Committed Capital to...

Beneficient is a financial services company, which engages in providing alternative assets, financial and investment services. It offers services to individual investors, wealth advisors, general partners, and institutional investors. It operates through the following segments: Ben Liquidity, Ben Custody, Customer ExAlt Trusts, and Corporate and Other. The Ben Liquidity segment offers liquidity products and services. The Ben Custody segment provides trust and custody administration services. The Customer ExAlt Trusts segment includes investments in alternative assets. The Corporate and Other segment relates to its overhead and administrative costs. The company was founded by Brad K. Heppner on June 6, 2023 and is headquartered in Dallas, TX.

Current Price	$0.8666
Prev Close	$0.8003
Open	$0.7678
Dividend Yield	0.00%
50-Day Moving Average	$0.6406
Beta	0.27
Avg. Volume	776,835.68
PE Ratio	-0.07

52-Week High	$1.56
52-Week Low	$0.2188
Market Capitalization	$88.84M
EPS (Annual)	$0.0645
Price to Book	-0.03
Revenue Per Employee	$14,527.27
Enterprise Value/EBITDA	N/A

BENF
Beneficient - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BENF News

BENFBeneficient - Ordinary Shares - Class A